BofA warns Fed risks policy mistake with early rate cuts
Investing.com - Day One Biopharmaceuticals reported on Monday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Day One Biopharmaceuticals announced earnings per share of $-0.53 on revenue of $0.00. Analysts polled by Investing.com EPS of $-0.52 on revenue of $0.00.
Day One Biopharmaceuticals 's are up 100% and is trading at $19.48 , still down 31.29% from its 52 week high of $28.35 set on Friday, August 12, 2022.
Day One Biopharmaceuticals follows other major Healthcare sector earnings this month
Day One Biopharmaceuticals's report follows an earnings beat by UnitedHealth on Friday, October 14, 2022, who reported EPS of $5.79 on revenue of $80.89B, EPS of $5.43 on revenue of $80.52B.
J&J had beat expectations on Tuesday, October 18, 2022 with third quarter EPS of $2.55 on revenue of $23.79B, for EPS of $2.52 on revenue of $23.46B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar